Two patients can look identical on a clinical chart: comparable LDL levels, similar blood pressure, no diabetes, and a matching family history of heart disease. Yet their outcomes can differ; one remains stable, while the other develops coronary heart disease (CHD).
Part of the reason is that standard risk factors often fail to capture the cumulative biological effects of an individual’s lifestyle and environment; factors like chronic stress, diet, sleep, and toxic exposures. Epigenetics, specifically DNA methylation, offers a breakthrough way to measure these effects.
DNA methylation is a biochemical process where a methyl group is added to cytosine bases in DNA (typically at CpG sites).
A simple way to think about this is that DNA methylation adds small chemical “tags” (methyl groups) to DNA that can act like dimmer switches, turning gene activity up or down without changing the underlying genetic code.
Increased Methylation: Often reduces gene expression (turning the gene "down").
Decreased Methylation: Can increase gene activity (turning the gene "up").
Unlike genetic mutations, methylation doesn't change your DNA sequence; it changes how your body reads that sequence. This makes it a dynamic "molecular readout" of your current health status.
Altered DNA methylation patterns have been identified across many disease areas, including:
Cancer
Neurological disorders
Autoimmune disease
Cardiovascular disease
In oncology, for example, hypermethylation of tumor suppressor genes can silence protective pathways and enable cancer progression. Importantly, many of these methylation changes are detectable before clinical disease is evident, making them valuable biomarkers for early risk detection.
A similar paradigm has emerged in cardiovascular disease.
Cardiovascular disease is the leading cause of death worldwide. While genetics play a role, a significant portion of risk is driven by environmental and lifestyle exposures accumulated over time. These exposures leave measurable epigenetic signatures in the blood, most commonly through changes in DNA methylation.
Correlation vs. Causation in Epigenetics
To use methylation findings clinically, we must distinguish between:
Correlation: An association where two factors move together but one doesn't cause the other.
Causation: A direct cause-and-effect relationship.
By identifying methylation changes that occur before the onset of clinical disease, clinicians can focus on useful biological signals rather than coincidental associations.
For example, two individuals may inherit similar genetic susceptibility to coronary heart disease (CHD). One individual who maintains healthier habits may exhibit methylation patterns associated with vascular protection and metabolic balance. Another, exposed to smoking, chronic stress, or adverse environmental factors, may develop methylation changes linked to inflammation, endothelial dysfunction, and early atherosclerotic activity, sometimes before abnormalities appear in cholesterol levels or cardiovascular imaging.
DNA methylation analysis provides a window into the active drivers of heart disease, including:
Inflammation and immune activation
Endothelial and vascular repair mechanisms
Lipid and cholesterol metabolism
Vascular remodeling and plaque development
Because these patterns reflect cumulative exposure, they are often detectable years before a major clinical event (like a heart attack) or abnormalities in cholesterol levels appear.
Epigenetics is more than just "lifestyle." While diet and exercise are vital, the epigenome is also shaped by factors patients may not even be aware of:
Air pollution
Industrial and agricultural chemicals
Water contaminants
Persistent organic pollutants (often referred to as “forever chemicals”)
DNA methylation analysis provides a way to detect the biological effects of these exposures, even when the exposure itself is no longer apparent.
Methylation-based biomarkers represent a shift toward Precision Medicine by offering three distinct advantages:
They integrate genetic, environmental, and lifestyle influences
They reflect cumulative biological burden over time
They can identify risk earlier than structural disease markers
Cardio Diagnostics’ clinical blood tests leverage advances in epigenetics and DNA methylation science to assess cardiovascular risk and disease at the molecular level.
Rather than measuring traditional risk factors alone, Cardio Diagnostics analyzes disease-associated methylation patterns linked to coronary heart disease biology. These patterns provide insight into whether key pathways related to atherosclerosis, inflammation, and vascular health are biologically active, often before symptoms or imaging abnormalities may arise.
Our goal is to:
Identify underlying biological risk;
Support earlier detection of disease activity and provide insight into biological pathways that may be driving disease;
Support personalized intervention strategies;
Complement existing clinical assessments.
Clinically reviewed by Dr. Rob Philibert, CMO, Cardio Diagnostics
